183.77 USD
-4.45 (-2.36%)
ICLR gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. ICLR has only an average score on both its financial health and profitability. ICLR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ICLR was profitable.
In the past year ICLR had a positive cash flow from operations.
Each year in the past 5 years ICLR has been profitable.
ICLR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ICLR has a better Return On Assets (3.63%) than 75.44% of its industry peers.
Looking at the Return On Equity, with a value of 6.42%, ICLR is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
ICLR's Return On Invested Capital of 6.74% is fine compared to the rest of the industry. ICLR outperforms 75.44% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 14.00%.
The last Return On Invested Capital (6.74%) for ICLR is above the 3 year average (5.80%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROIC | 6.74% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
1.3 Margins
The Profit Margin of ICLR (7.40%) is better than 75.44% of its industry peers.
ICLR's Profit Margin has declined in the last couple of years.
ICLR's Operating Margin of 13.99% is fine compared to the rest of the industry. ICLR outperforms 73.68% of its industry peers.
In the last couple of years the Operating Margin of ICLR has remained more or less at the same level.
Looking at the Gross Margin, with a value of 28.15%, ICLR is doing worse than 77.19% of the companies in the same industry.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% |
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
Compared to 1 year ago, ICLR has less shares outstanding
ICLR has more shares outstanding than it did 5 years ago.
ICLR has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.13 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score (2.13) which is in line with its industry peers.
The Debt to FCF ratio of ICLR is 3.53, which is a good value as it means it would take ICLR, 3.53 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.53, ICLR is doing good in the industry, outperforming 78.95% of the companies in the same industry.
ICLR has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
ICLR's Debt to Equity ratio of 0.31 is in line compared to the rest of the industry. ICLR outperforms 49.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Altman-Z | 2.13 |
ROIC/WACC0.75
WACC8.93%
2.3 Liquidity
ICLR has a Current Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR has a worse Current ratio (1.06) than 85.96% of its industry peers.
ICLR has a Quick Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR's Quick ratio of 1.06 is on the low side compared to the rest of the industry. ICLR is outperformed by 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
ICLR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.23% yearly.
The Revenue has decreased by -2.46% in the past year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
3.2 Future
The Earnings Per Share is expected to grow by 5.61% on average over the next years.
ICLR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.38% yearly.
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.61%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.93 indicates a correct valuation of ICLR.
Compared to the rest of the industry, the Price/Earnings ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 96.49% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.00. ICLR is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 13.47, the valuation of ICLR can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 96.49% of the companies listed in the same industry.
ICLR's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.70.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.93 | ||
| Fwd PE | 13.47 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICLR is valued cheaper than 98.25% of the companies in the same industry.
94.74% of the companies in the same industry are more expensive than ICLR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.55 | ||
| EV/EBITDA | 11.37 |
4.3 Compensation for Growth
The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.91
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
5. Dividend
5.1 Amount
No dividends for ICLR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ICLR (1/9/2026, 2:09:46 PM)
183.77
-4.45 (-2.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.53%
Inst Owner Change0%
Ins Owners0.66%
Ins Owner ChangeN/A
Market Cap14.03B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts76.67
Price Target209.67 (14.09%)
Short Float %3.68%
Short Ratio2.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-0.06%
PT rev (3m)-4.74%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-1.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.93 | ||
| Fwd PE | 13.47 | ||
| P/S | 1.73 | ||
| P/FCF | 14.55 | ||
| P/OCF | 12.31 | ||
| P/B | 1.5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.37 |
EPS(TTM)13.19
EY7.18%
EPS(NY)13.65
Fwd EY7.43%
FCF(TTM)12.63
FCFY6.87%
OCF(TTM)14.93
OCFY8.13%
SpS106.11
BVpS122.25
TBVpS-38.98
PEG (NY)N/A
PEG (5Y)0.91
Graham Number190.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 6.98% | ||
| ROICexgc | 176.34% | ||
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% | ||
| FCFM | 11.9% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 45.31% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.92% | ||
| Profit Quality | 160.84% | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 2.13 |
F-Score6
WACC8.93%
ROIC/WACC0.75
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.61%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.2%
EBIT Next 3Y1.96%
EBIT Next 5Y4.34%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%
ICON PLC / ICLR FAQ
Can you provide the ChartMill fundamental rating for ICON PLC?
ChartMill assigns a fundamental rating of 5 / 10 to ICLR.
What is the valuation status for ICLR stock?
ChartMill assigns a valuation rating of 6 / 10 to ICON PLC (ICLR). This can be considered as Fairly Valued.
How profitable is ICON PLC (ICLR) stock?
ICON PLC (ICLR) has a profitability rating of 6 / 10.
What is the valuation of ICON PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ICON PLC (ICLR) is 13.93 and the Price/Book (PB) ratio is 1.5.
How financially healthy is ICON PLC?
The financial health rating of ICON PLC (ICLR) is 5 / 10.